First Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors, a Phase II Trial
OBJECTIVES: I. Assess the therapeutic activity of temozolomide as first line chemotherapy in
patients with recurrent oligodendroglial tumors after radiation therapy. II. Assess the
objective response and duration of response of these patients given this treatment. III.
Characterize the acute side effects of temozolomide in this patient population.
OUTLINE: This is an open label, multicenter study. Patients receive oral temozolomide on
days 1-5. Courses are repeated every 28 days. Treatment continues for a maximum of 12
courses in the absence of unacceptable toxicity or disease progression. Patients are
followed every 3 months until disease progression.
PROJECTED ACCRUAL: A total of 15-33 patients will be accrued for this study.
Primary Purpose: Treatment
Martin J. van Den Bent, MD
Daniel Den Hoed Cancer Center at Erasmus Medical Center
United States: Federal Government